Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,602,887
  • Shares Outstanding, K 106,374
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ 45 M
  • EBITDA $ 42 M
  • 60-Month Beta 0.29
  • Price/Sales 4.76
  • Price/Cash Flow 37.71
  • Price/Book 5.53

Options Overview Details

View History
  • Implied Volatility 55.62% (+2.22%)
  • Historical Volatility 69.45%
  • IV Percentile 29%
  • IV Rank 18.49%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 13) 3.11 (9.19%)
  • Put/Call Vol Ratio 7.08
  • Today's Volume 1,559
  • Volume Avg (30-Day) 2,470
  • Put/Call OI Ratio 1.40
  • Today's Open Interest 38,250
  • Open Int (30-Day) 41,831
  • Expected Range 30.76 to 36.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.40
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -264.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.66 +18.18%
on 02/19/26
41.92 -19.20%
on 02/10/26
-6.96 (-17.05%)
since 02/06/26
3-Month
28.66 +18.18%
on 02/19/26
89.00 -61.94%
on 12/15/25
-52.24 (-60.66%)
since 12/05/25
52-Week
28.66 +18.18%
on 02/19/26
117.33 -71.13%
on 03/31/25
-20.43 (-37.62%)
since 03/06/25

Most Recent Stories

More News
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

NEW ORLEANS , March 6, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications...

CORT : 33.87 (-0.50%)
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

NEW YORK , March 5, 2026 /PRNewswire/ --

CORT : 33.87 (-0.50%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT

NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT)....

CORT : 33.87 (-0.50%)
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps"

CORT : 33.87 (-0.50%)
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , March 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept " or "the Company") (NASDAQ: CORT...

CORT : 33.87 (-0.50%)
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 5, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics...

CORT : 33.87 (-0.50%)
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept”...

CORT : 33.87 (-0.50%)
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of...

CORT : 33.87 (-0.50%)
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who...

CORT : 33.87 (-0.50%)
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps"

CORT : 33.87 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 35.56
2nd Resistance Point 34.87
1st Resistance Point 34.37
Last Price 33.87
1st Support Level 33.18
2nd Support Level 32.49
3rd Support Level 31.99

See More

52-Week High 117.33
Fibonacci 61.8% 83.46
Fibonacci 50% 73.00
Fibonacci 38.2% 62.53
Last Price 33.87
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar